Recent publications

• Duration of Antifungal Therapy in Disseminated Coccidioidomycosis Patients: A Real-World Treatment Utilization Study April 27, 2026
  Background: Disseminated coccidioidomycosis (DCM) often requires prolonged antifungal therapy (AFT). Real-world data on AFT duration in DCM are limited. We evaluated time to AFT discontinuation among patients with DCM in the United States clinical practice. Methods: This retrospective, longitudinal study used STATinMED data (2016-2024). Patients had ≥1 International Classification of Diseases, Tenth Revision (ICD-10) code […]
  Craig I Coleman
• Periodontal Disease and Risk of Heart Failure: A Systematic Review and Meta-Analysis April 24, 2026
  Periodontal disease (PD) has been hypothesized to influence the risk of heart failure (HF), but the evidence remains inconclusive. We conducted a systematic review to evaluate the association between PD and HF. PubMed, Embase, Scopus, and Web of Science were searched from inception to October 2024. We selected cohort studies assessing the association between PD […]
  German Valenzuela-Rodríguez
• Comment on "Adopting Race-Free Estimated Glomerular Filtration Rate for Unifying Medication-Related Decision-Making: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy" April 20, 2026
  No abstract
  Nicole L Metzger
• The Impact of a Pharmacist-Driven, Interprofessional Lipid Optimization Workflow in a Transitions of Care (LOW-TOC) Pilot Program April 20, 2026
  CONCLUSIONS: The implementation of the LOW-TOC approach to CV team-based lipid management was associated with significantly increased optimizations compared with the standard process typically utilized in many health systems. These findings support the utility of pharmacists leading the CV team in optimizing lipid management using a population health model in TOC settings.
  Jillian Searle
• Identification and Characterization of Mitragynine or 7-Hydroxymitraynine Oral Dosage Form Products That Appeal to Children April 15, 2026
  CONCLUSIONS: Mitragynine and 7-hydroxymitragynine are present in many products that could cause small children and teens to be exposed.
  C Michael White
• Contemporary Immunosuppression in Simultaneous Heart-Kidney Transplantation: A United Network for Organ-Sharing Database Analysis April 8, 2026
  CONCLUSION: Contemporary SHKT recipients experience similar 1-year outcomes across induction strategies. Basiliximab may be sufficient for standard-risk SHKT recipients.
  Xinyi Huang
• 10th anniversary: The development, implementation, and evaluation of a novel peer-assisted learning (PAL) program April 3, 2026
  CONCLUSION: The outcomes of this report suggest that including various PAL modalities in the didactic pharmacy curriculum can increase student confidence in learning and perceived performance on assessments. The PAL program presented appears feasible, effective, and sustainable.
  Nathaniel M Rickles
• Association of the C-reactive protein-triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study April 2, 2026
  No abstract
  Ramin Assempoor
• Efficacy of Oral Arginine as Treatment to Improve Height in Prepubertal Children With Idiopathic Short Stature: A Systematic Review and Meta-Analysis March 30, 2026
  CONCLUSION: Oral arginine administered for 12 months may not affect growth. Well-designed RCTs are required.
  Manuel André Virú-Loza
• It's time to improve antithrombotic therapy! A global perspective for antithrombotic stewardship March 19, 2026
  Antithrombotic drugs are a class of medications with the highest rates of serious and life-threatening adverse events, many of which are preventable with proper knowledge and systems of management. Antithrombotic stewardship is a care model shown to improve outcomes and is gaining traction throughout the world. Stewardship implies a comprehensive system of care employing coordinated, […]
  W Ageno
• Incidence and outcomes of major bleeding among first-time oral factor Xa inhibitor users: multinational observational cohort studies March 18, 2026
  CONCLUSION: Results of this large-scale study indicate that the incidence of major bleeding remains elevated during the first 3 years after initiating FXai treatment and that these bleeding events seemed to be associated with significant mortality.
  Alexander T Cohen
• Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials March 14, 2026
  Background/Objectives: There are conflicting results on the effects of ferric derisomaltose (FDM) vs. iron sucrose (IS) for treatment of iron deficiency anemia (IDA). We systematically assessed the efficacy and safety of these treatments. Methods: We searched Ovid MEDLINE, Web of Science, Pubmed, and Cochrane Central for randomized controlled trials (RCTs) comparing the efficacy and/or safety […]
  Lokman H Tanriverdi
• Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States March 11, 2026
  CONCLUSIONS: Finerenone was primarily prescribed as a pillar of therapy that is used in combination with complementary medications in patients with T2D and CKD, aligning with clinical guidelines and regulatory labeling.
  Csaba P Kovesdy
• Bury my axe in wounded knee: A case of native knee septic arthritis caused by multidrug resistant <em>Lomentospora</em> <em>prolificans</em> March 9, 2026
  A 39-year-old male presenting with swelling and pain in the left knee after traumatic injury was diagnosed with rapidly progressive septic arthritis of the knee due to pan-resistant Lomentospora prolificans. While L. prolificans is an environmental mold, it infrequently causes infection in immunocompetent patients. These hosts most commonly suffer soft tissue or osteoarticular infections following […]
  Weston Carpenter
• Using the ACCP Toolkit to Evolve the PharmD Curriculum March 1, 2026
  CONCLUSION: Using the ACCP Toolkit in the curricular assessment process was effective in identifying areas of curricular overload and informing areas for improvement in a subsequent curricular revision, leading to adjustment of credits and time spent on pharmacotherapy topics within courses.
  Jennifer Luciano
• Short-Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States February 24, 2026
  CONCLUSIONS: Both LVAD and HT had comparable burdens on resources and short-term rehospitalization risk.
  Balaphanidhar Mogga
• Efficacy and harms of polypills for cardiovascular disease prevention: A systematic review and meta-analysis of randomized controlled trials February 20, 2026
  CONCLUSIONS: In primary and secondary prevention settings, polypills had moderate reductions of CV outcomes, small effects on CV risk factors, and small increases of AEs.
  Brian M Portela
• Risk scoring for the primary prevention of cardiovascular disease February 17, 2026
  This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of evaluating and providing cardiovascular disease (CVD) risk scores in adults without prevalent CVD on cardiovascular outcomes, risk factor levels, preventive medication prescribing, and health behaviours.
  Adrian V Hernandez
• The 2025 Invitational Summit on Medicaid Payment for Pharmacist Patient Care Services: Meeting proceedings February 15, 2026
  No abstract
  Marie A Smith
• Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown February 14, 2026
  CONCLUSION AND RELEVANCE: We found little justification for adding nutrients or docusate sodium to combination subcutaneous semaglutide or tirzepatide products. There is a rationale for adding ondansetron, but evidence for subcutaneous administration is lacking. There is a rationale for fashioning sublingual or ODT formulations, but whether these formulations offer advantages over innovator oral tablets has […]
  Jordyn Belcourt